Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 14/20 | 0.55 |
| ▸ | ESR1 | P03372 | 2/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PARG | Q86W56 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20893357 | 0.82 | HIF1A (0.71) | HIF1APARGUSP2 | |
| SCHEMBL3852307 | 0.81 | VDR (0.65) | HIF1AAR | |
| SCHEMBL1474090 | 0.79 | MEN1 (0.60) | HIF1ANPC1MAPTRAB9APARG | |
| SCHEMBL5972114 | 0.78 | HIF1A (0.52) | HIF1AARPARG | |
| SCHEMBL3853421 | 0.78 | ESR1 (0.52) | ESR1ARESR2MAPTUSP2 | |
| SCHEMBL19661983 | 0.77 | KCNH2 (0.66) | HIF1ANPC1MAPTRAB9APARG | |
| SCHEMBL10743403 | 0.76 | GPR35 (0.64) | HIF1ANPC1MAPTRAB9APARG | |
| SCHEMBL3850703 | 0.75 | ESR1 (0.52) | ESR1ARESR2MAPTRAB9A | |
| SCHEMBL16732898 | 0.75 | KDM4E (0.62) | HIF1ANPC1MAPTRAB9APARG | |
| SCHEMBL788918 | 0.75 | KCNH2 (0.67) | HIF1ANPC1MAPTRAB9APARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106095-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | HIF1A 872/4885ESR1 174/4885AR 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.